ArticleNew microbes and new infections2026
Analysing outbreak signals, 2013-2024: The amsterdam UMC centre for Tropical Medicine and Travel Medicine Epi Alert programme - an observational study.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Timely, clinically relevant outbreak intelligence is critical in an evolving infectious disease landscape. Over twelve years, the Amsterdam UMC Centre of Tropical Medicine and Travel Medicine produced weekly Methods: We conducted a retrospective analysis of all EAs (April 2013-December 2024). Data from 454 bulletins yielded 10,619 entries classified by pathogen type, disease category, and location. The study was reported in accordance with the STROBE guidelines for observational studies. Results: Viral infections predominated (7,234/10,619; 68%), followed by bacterial (2,562; 24%), parasitic (646; 6%), and fungal (83; 1%) diseases. Arboviruses comprised 46% of viral entries (3,312/7,234), mainly dengue (1,210; 17%), chikungunya (328; 5%), and West Nile fever (314; 4%). Viral haemorrhagic fevers accounted for 17% (1,209/7,234) of all viral entries, predominantly Ebola virus disease (321; 4%), yellow fever (292; 4%), and Crimean-Congo haemorrhagic fever (246; 3%). Measles featured prominently (1,114/10,619; 11%). Reporting favoured English-language sources with higher internet visibility and well-resourced surveillance systems. Rare/emerging pathogens (e.g. Powassan, Oropouche, Kyasanur Forest disease viruses) were consistently captured. At analysis, 67% of hyperlinks were defunct (7,150/10,619). Conclusions: Although two-thirds of cited hyperlinks had become at the time of analysis, the EA archive offers durable, clinically relevant outbreak intelligence supporting diagnosis, travel advice, education. While selective, it captures emerging, rare and geographically unexpected infections relevant to clinical reasoning. Integration into ESCMID's Emerging Infections Subcommittee since mid-2025 ensures continuity and supports development into a searchable, continuously updated resource.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.